Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast

[News]

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

More... (http://www.news-medical.net/news/20140725/Phase-3-trial-NEXAVAR-tablets-fail-to-meet-primary-endpoint-in-HER2-negative-breast-cancer-patients.aspx)